| Seed Fund |
| Organization | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) |
| Source of funding | |
| Scheme | Seed Fund |
| Type of funding | Other |
| Funding Amount | 0 |
| Description | |
| Range of funding | Undefined |
| Target investees | Entrepreneurs |
| Note | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With up to US$480 million to invest in 2016-22, CARB-X funds the best science from around the world. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent, diagnose and treat life-threatening bacterial infections. |
| Purpose | Accelerate a diverse portfolio of innovative antibacterial products towards clinical development and regulatory approval with funding, expert support and cross-project initiatives. We focus on the dangerous bacteria identified by the WHO and CDC priority lists. |
| Focus area | Biotechnology/ Biomedical/ Health Technologies |
| Provides Funds For | A, B, C, D, |
| Scheme Type | Ongoing scheme |
| Recommended scheme | |
| Scheme status | Live scheme |
| More detail.. | Link |
